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Innate and adaptive immunity plays important roles in the development and progression of
cancer and it is becoming apparent that tumors can influence the induction of potentially
protective responses in a number of ways. The prevalence of immunoregulatory T
cell populations in the circulation and tumors of patients with cancer is increased and
the presence of these cells appears to present a major barrier to the induction of
tumor immunity. One aspect of tumor-mediated immunoregulation which has received
comparatively little attention is that which is directed toward natural killer (NK) cells,
although evidence that the phenotype and function of NK cell populations are modified in
patients with cancer is accumulating. Although the precise mechanisms underlying these
localized and systemic immunoregulatory effects remain unclear, tumor-derived factors
appear, in part at least, to be involved. The effects could be manifested by an altered
function and/or via an influence on the migratory properties of individual cell subsets. A
better insight into endogenous immunoregulatory mechanisms and the capacity of tumors
to modify the phenotype and function of innate and adaptive immune cells might assist
the development of new immunotherapeutic approaches and improve the management
of patients with cancer. This article reviews current knowledge relating to the influence
of tumors on protective anti-tumor immunity and considers the potential influence that
radiation-induced effects might have on the prevalence, phenotype, and function of innate
and adaptive immune cells in patients with cancer.
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INTRODUCTION
For many years, the paradigm on which the majority of
immunotherapeutic approaches for the treatment of cancer has
been based, is that adaptive immune responses to tumors are
similar to those that are induced in the generation of immu-
nity to infectious pathogens. Although this is, in part at least,
the case, a fundamental difference is that responses induced by
infectious pathogens are driven by exogenous (“foreign”) pro-
teins/molecules, whereas those to tumors must be induced by
endogenous (“self”) proteins. Although not all tumor antigens
are “self” antigens (e.g., EBV antigens, mutated p53), themajority
are. For effective immunity, it is therefore necessary to overcome
the well-developed capacity of the immune system to regulate
responses to self-antigens and tissues.
Tumors can produce immunosuppressive factors such as
IL-10, TGF-β, and vascular endothelial growth factor (VEGF).
Tumor-derived cytokines such as IL-10 and TGF-βmight protect
against the development of anti-tumor immunity by influenc-
ing the functional capacity of antigen presenting cells (APCs)
such as dendritic cells (DCs), and by promoting the genera-
tion/differentiation/expansion of immunoregulatory T cell pop-
ulations which have the capacity to control and prevent immune
responses (Ghiringhelli et al., 2005b; Liu et al., 2007; Mahnke
et al., 2007a; Biollaz et al., 2009; Conroy et al., 2012; Multhoff
and Radons, 2012). The biology of different immunoregulatory
T cell populations and the functional significance of tumor-
associated immunoregulatory T cells have recently been reviewed
(Sakaguchi, 2011; Shevach, 2011; Facciabene et al., 2012; Savage
et al., 2013). The net result is a complex relationship between
tumors and elements of the protective immune system which has
profound influences on the progression and treatment of cancer.
It is on the influence of tumors on innate and adaptive immunity
by tumors that this article focusses.
IMMUNOREGULATORY T CELLS
It is now known that thymic deletion of potentially self-reactive
T cells cannot explain the lack of immune responsiveness to self-
tissues and antigens, as the normal T cell repertoire includes low
affinity T cells that are reactive against a number of self-peptides.
Mechanisms that are capable of controlling the development of
immune responses to self-antigens in the periphery must there-
fore be present. Over the last few years an anti-inflammatory
activity has been shown to segregate, in part at least, into a natu-
rally occurring CD4+ T cell subset which constitutively expresses
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the α chain of the IL-2 receptor (CD25) (Shevach, 2002; Gavin
and Rudensky, 2003; Wood and Sakaguchi, 2003; Lee et al., 2004;
Waldmann et al., 2004).
In addition to CD25, these cells also express other antigens
including the intracellular transcription factor forkhead box p3
(Foxp3) (Sakaguchi, 2004), glucocorticoid-induced TNF recep-
tor family-related gene (GITR), the immunoregulatory antigen
CTLA-4, neuropilin-1 (Bruder et al., 2004) and, in the case of
humans, low cell surface levels of CD127 (Liu et al., 2006b;
Seddiki et al., 2006). The depletion or absence of these cells
triggers autoimmune destruction of a variety of tissues (Asano
et al., 1996; Suri-Payer et al., 1998; McHugh and Shevach,
2002). Although a multitude of immunoregulatory T and B
cell populations have, and are, being discovered and reported
upon, CD4+CD25high Treg cells are regarded as being intimately
involved in the governance of peripheral self-tolerance (Shevach,
2002, 2011; Nelson, 2004; Sakaguchi, 2004, 2011; Facciabene
et al., 2012; Savage et al., 2013).
CD4+CD25high Treg cells develop in the thymus and represent
5–10% of the peripheral CD4+ T cell compartment. Although the
expression of Foxp3 is currently accepted as being the most effec-
tive marker of Treg cells in mice and humans (Graca, 2005), there
is evidence that some Foxp3 negative cells can be suppressive, and
Foxp3 is not therefore a definitive marker for Treg cells (Gavin
et al., 2007; Curiel, 2007a; Wan and Flavell, 2007). The sup-
pressive effects of naturally-occurring Treg cells are mediated via
relatively far-reaching soluble factors and more intimate cell–cell
contact, as well as direct cytotoxic effects on effector cell popula-
tions (Schmetterer et al., 2012). These cells are also key regulators
of anti-tumor immunity (Facciabene et al., 2012; Lindau et al.,
2013; Savage et al., 2013).
According to Savage et al. (2013), the biology of tumor-
associated Treg cells involves two developmental pathways: (1) the
recognition of self-antigen by developing thymocytes within the
thymus leads to the development of naturally-occurring Foxp3+
Treg (nTreg) cells and (2), naïve CD4+ T cells recognize a tumor-
associated or tumor-specific antigen at extrathymic sites and, after
being activated, develop into an inducible Foxp3+ Treg cell (iTreg
or Tr1) under a variety of conditions that facilitate/enable tumor
immune evasion. These conditions include not only antigen pre-
sentation under sub-immunogenic or non-inflammatory condi-
tions, but also chronic inflammation and infections. The observed
selective accumulation of Treg cells in the tumor microenviron-
ment suggests that this process can also be driven by tumors.
As hypothesized by Adema and colleagues (Jacobs et al.,
2012), four non-mutually exclusive mechanisms can account
for the accumulation of Treg cells in the tumor microenvi-
ronment: (1) Chemokine secretion induces the selective migra-
tion and retention of Treg cells that constitutively express
high levels of CCR4 (CCL22, CCL2). (2) Secretion of anti-
inflammatory mediators such as TGF-β and indoleamine 2,3-
dioxygenase (IDO) converts conventional (naïve) T cells to
Treg cells, either directly or via the actions of antigen-
presenting cells; (3) A selective survival advantage of Treg
cells over other tumor-infiltrating lymphocytes occurs when
negative costimulatory signals selectively influence effector
T cells (PD-L1, FasL). Treg cells also induce receptor-mediated
or cytotoxin-mediated Teff cell depletion; (4) tumor-derived
immunosuppressive factors such as IL-10 and TGF-β promote
the expansion of nTreg cells and the de novo generation of iTreg
cells.
The different origins of iTreg cells (non-inflammatory, inflam-
matory) results in distinct properties of these cells which
include differential stabilities (Bilate and Lafaille, 2012). iTreg
cells are also generated during homeostasis of the gut and in
cancer, although some cancers favor the expansion of nTreg
cells. Both pathways converge in the tumor environment and
this leads to context-dependent Treg cell functions such as
the promotion of metastasis and angiogenesis, as well as the
limitation of inflammation and blockage of anti-tumor immu-
nity in response to inflammatory conditions (tissue/organ-
specific) and the tumor microenvironment, respectively. The
suppressive effect of nTreg cells is mediated via cell contact-
dependent mechanisms such as granzyme B/perforin and
Fas/FasL (Jonuleit et al., 2001). In contrast, iTreg cells mediate
suppression in a cell contact-independent manner (Roncarolo
et al., 2006; Bergmann et al., 2008; Mandapathil et al.,
2010).
IMMUNOREGULATORY T CELLS AND ANTI-TUMOR
IMMUNITY
As stated above, a wealth of historical and more recent evi-
dence now suggests that CD4+CD25high Treg cell populations
influence the presence, induction, and maintenance of protective
anti-tumor immunity (Raimondi et al., 2007; Facciabene et al.,
2012; Lindau et al., 2013; Savage et al., 2013), and their association
with the progression of malignant disease has been highlighted by
a number of observations (Table 1).
These cells present a significant barrier to the induction of
tumor immunity (Raimondi et al., 2007; Facciabene et al., 2012;
Lindau et al., 2013; Savage et al., 2013), and reducing their
numbers and/or function is therefore likely to be of therapeutic
potential. The evidence that the depletion of CD4+CD25high Treg
cells enhances the capacity to induce cellular and humoral immu-
nity to Her-2 which is expressed on primary andmetastatic breast
cancer cells (Fulton et al., 2006) confirms the importance of these
cells and highlights the importance of improving our understand-
ing of the influence of the breast tumor microenvironment on
protective innate and adaptive anti-tumor immunity.
It is also important to appreciate that other immunoreg-
ulatory T cells such as the adaptive or inducible populations
(iTreg) are phenotypically and functionally different to the pop-
ulation discussed above and resistant to apoptosis or oncolog-
ical therapies (Whiteside, 2012). The potent capacity of these
cells to suppress effector T cell function involves immuno-
suppressive cytokines such as TGF-β, IL-10, prostaglandin E2,
and adenosine that can be produced by solid tumors and/or
Treg cells themselves (Erdman et al., 2003; Roncarolo et al.,
2006; Bergmann et al., 2008; Mandapathil et al., 2010; Conroy
et al., 2012). As mentioned before, differentiation of naïve CD4+
T cells into iTreg cells in the periphery is encouraged by tumor
antigen in the presence of certain cytokines such as IL-2, IL-
10, and TGF-β (Levings et al., 2001b; Bergmann et al., 2007,
2008).
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Table 1 | Influence of CD4+CD25highTreg cells on anti-tumor immunity.
Observation References
CD4+CD25high Treg cells are potent inhibitors of anti-tumor immune responses and the depletion of Treg
cells promotes the rejection of several transplantable murine tumor cell lines including melanoma,
fibrosarcoma, leukaemia, and myeloma
Sakaguchi et al., 1995; Onizuka et al.,
1999; Shimizu et al., 1999; Steitz et al.,
2001; Jones et al., 2002
CD4+CD25high Treg cells impair responses to tumor-associated antigens that are expressed as
self-antigens
Sutmuller et al., 2001; Golgher et al., 2002
Increased numbers of functionally suppressive CD4+CD25high Treg cells are present in the peripheral
blood of patients with breast cancer, and also in the tumor microenvironment
Liyanage et al., 2002; Wolf et al., 2003
CD4+CD25high T cells from patients with epithelial malignancies are anergic to T cell receptor stimulation
and suppress the proliferation of CD4+CD25− T cells
Wolf et al., 2003
Using an experimental murine system and CT26 tumor cells, depletion of CD25high Treg cells has been
shown to allow the host to induce both CD4+ and CD8+ anti-tumor responses following tumor challenge.
The capacity of the host to mount this anti-tumor response is lost once the number of CD25high Treg
cells is restored over time
Casares et al., 2003
The depletion of CD25high Treg cells before immunization with AH1 (a cytotoxic T cell determinant from
CT26 tumor cells) permits the induction of a long-lasting anti-tumor immune response which is not
observed if immunization is conducted in the presence of CD25high Treg cells
Casares et al., 2003
CD4+CD25high Treg cells alone can prevent effective adoptive immunotherapy Antony et al., 2005
CD4+CD25high Treg cells can impair CD8+ T cell immunity against tumor/self-antigens Antony et al., 2005
Depletion of CD4+CD25high Treg cells promotes a tumor-specific immune response in mice bearing
pancreatic cancers
Viehl et al., 2006
The depletion of CD4+CD25+Foxp3high Treg cells increases the efficacy of vaccination approaches that
are aimed at increasing cellular and humoral immunity to Her-2 which is expressed on primary and
metastasized breast cancer cells
Fulton et al., 2006
The proportion of CD4+CD25highTreg cells is elevated in the peripheral blood of patients with
hepatocellular carcinoma (HCC), and their levels positively correlate with tumor burden
Cao et al., 2007
Depletion of CD25+ cells results in an accumulation of CD4+ and CD8+ T cells and NK cells producing
IFN-γ in mesothelioma tumor tissue
Rudge et al., 2007
In a syngeneic murine glioma model, combining Treg cell depletion with administration of blocking
CTLA-4mAbs further boosted glioma-specific CD4+ and CD8+ effector T cells resulting in complete
tumor eradication without any signs of autoimmunity. These data illustrate that intratumoral accumulation
and activation of CD4+FoxP3+ Treg cells act as a dominant immune escape mechanism for gliomas
Grauer et al., 2007
The frequency of CD4+CD25high Treg increases during disease progression and also following cancer
therapy in HNSCC patients with no evident disease compared to untreated patients with active disease
Strauss et al., 2007
CD4+CD25highTreg secrete IL-10 and TGF-β and mediate immunosuppression in the tumor environment in
a cell contact-independent manner
Strauss et al., 2007
Low doses of IL-2 in combination with DC vaccination are able to expand CD4+CD25+Foxp3+ Treg cells
in metastatic renal cell carcinoma patients suggesting that a combination of DCS-mediated
immunotherapy and Treg depletion may be a promising approach in enhancing the ability of vaccination
therapy to elicit effective anti-tumor responses in cancer patients
Berntsen et al., 2010
FOXP3+ Treg cells predict poor survival in patients with cyclooxygenase-2–positive uveal melanoma Mougiakakos et al., 2010
AML and high-risk MDS patients have significantly larger CD4+CD25high/CD4 and
CD4+CD25highFoxP3+/CD4 populations in the periphery compared to patients with autoimmune
hematologic diseases and controls, respectively
Moon et al., 2011
(Continued)
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Table 1 | Continued
Observation References
Chemotherapy significantly decreased CD4+CD25high Treg cell numbers and FOXP3 mRNA expression in
advanced esophageal cancer patients
Xu et al., 2011
The frequency of CD4+CD25high Treg cells is elevated in HNSCC patients and may be modulated by
radiochemotherapy
Schuler et al., 2011
Neoadjuvant sorafenib treatment significantly reduced the percentage of tumor-infiltrating Treg cells in
renal cell carcinoma patients
Desar et al., 2011
INFLUENCE OF TUMORS AND TUMOR-RELATED FACTORS
ON IMMUNOREGULATORY T CELL POPULATIONS
There is now a wealth of evidence indicating that factors
present in the tumor microenvironment can foster immune
tolerance by generating and inducing the functional capacity of
CD4+CD25high Treg cell populations (Zou, 2005) and the induc-
tion of antigen-specific regulatory T cells from naïve cells (Zhou
and Levitsky, 2007). However, the mechanism(s) underlying the
recruitment, expansion and/or activation of these cells remain
unclear.
The preferential accumulation of functional regulatory T cell
populations in tumors could result from an increased recruit-
ment, decreased emigration, and/or the local conversion of
naïve T cells to regulatory populations by tumor-derived factors.
The conversion of naïve T cells into inducible immunoregu-
latory T cells involves TGF-β and other factors, and has been
reviewed elsewhere (Dons et al., 2012). Should such factors be
involved, then their presence might be patient/tumor and/or
treatment-specific. Chemokines play a role in migratory events,
as tumor cells andmicroenvironmental macrophages produce the
chemokine CCL22, which mediates trafficking of Treg cells to the
tumor (Curiel et al., 2004). More recently, it has been shown that
tumor hypoxia promotes the recruitment of regulatory T cells to
tumors via the induction of the chemokine CCL28 (Facciabene
et al., 2011).
A number of tumor-related events could be influential for
the induction of regulatory T cell populations. Regulatory T
cells can be induced by antigenic stimulation both in vitro and
in vivo [induced regulatory T cells (Bluestone and Abbas, 2003;
Vigouroux et al., 2004)], and these can mediate tumor-specific T
cell tolerance (Zhou and Levitsky, 2007). Tumors might therefore
release antigens and/or other non-antigen-specific factors that
activate Treg cells, thereby mediating tumor-related immunoreg-
ulation (Antony et al., 2005). It is also possible that factors
expressed on, or released from tumors, might promote the devel-
opment and expansion of CD4+CD25high Treg cells.
In this regard, it is known that the prevalence of
CD4+CD25high T cells in tumor draining lymph nodes and
the spleens of mice bearing the pancreatic adenocarcinoma
Pan02, increases with tumor growth (Liyanage et al., 2006).
Furthermore, tumor-related factors activate CD4+CD25high
Treg cells (Li et al., 2005), expand CD4+CD25high Treg cells and
enhance their suppressive capacity (Cao et al., 2007). Gastric
cancer cells induce human CD4+Foxp3+ regulatory T cells via
the production of TGF-β (Yuan et al., 2011). It has also been
shown that tumor-related factors activate CD4+CD25high Treg
cells (as indicated by increasing their expression of CD69) (Li
et al., 2005), expand CD4+CD25high Treg cells and enhance their
suppressive capacity (Cao et al., 2007).
It is also possible that the mode of tumor cell death, whether
this is induced by normal cell turnover or by therapeutic interven-
tion can influence the qualitative nature and effectiveness of the
immune response induced. Cellular necrosis is an inflammatory
stimulus, whereas apoptosis can have anti-inflammatory conse-
quences, at least some of which appear to be mediated via the
induction of immunoregulatory T cell populations (Groux et al.,
1997; Steinbrink et al., 1997, 1999; Lee et al., 1998; Levings et al.,
2001a; Yamagiwa et al., 2001).
EFFECT OF DECREASING REGULATORY T CELLS ON
ANTI-TUMOR IMMUNITY
Modifying the numbers and function of immunoregulatory T cell
populations could be of significant therapeutic benefit to patients
with cancer (Ménétrier-Caux et al., 2012). One approach which
has been considered is the use of DAB(389)IL-2 (also known
as denileukin diftitox and ONTAK). This is a recombinant IL-
2/diphtheria toxin fusion protein which delivers diphtheria toxin
to CD25+ cells and thereby abrogates the immunoregulatory
influence of CD4+CD25+ Treg cells (Dannull et al., 2005).
Following internalization, protein translation is inhibited and tar-
geted cells undergo apoptosis (Foss, 2000). The administration of
ONTAK has been shown to reduce the number of circulating Treg
cells and to enhance the magnitude of vaccine-induced, tumor-
specific immune responses in patients with renal cell carcinoma
(Dannull et al., 2005). It also improves immunity in patients
with melanoma (Chesney et al., 2006; Mahnke et al., 2007b).
ONTAK has also been shown to decrease the number of circu-
lating CD4+CD25+ Treg cells and the suppression mediated by
these cells in patients with ovarian, lung, breast, and pancreatic
cancer (Curiel, 2007b). It also improves immunity and induces
tumor regression in a murine model of breast cancer (Knutson
et al., 2006).
Daclizumab (Zenapex®) and basiliximab (Simulect®) are
anti-human CD25 monoclonal antibodies (mAbs) which have
been approved for use in autoimmune disease, transplan-
tation, and cancer, including HTLV-1-induced adult T cell
lymphoma/leukemia (reviewed in Ménétrier-Caux et al.,
2012). Daclizumab treatment durably reduces circulating
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CD25highFOXP3+ Treg cell numbers and promotes the emer-
gence of cancer-specific cytotoxic T cells after vaccination with
cancer antigen peptides (hTERT/survivin) in patients with
metastatic breast carcinoma (Rech and Vonderheide, 2009).
However, one issue which has to be considered using such
approaches is the potential to influence the activated effector cells
which also express CD25.
It is also possible to block the function of Treg cells via a
number of cell surface receptors (reviewed in Ménétrier-Caux
et al., 2012). These approaches include the use of the anti-
CTLA-4 antagonist mAb, two humanized forms of which are
available—BMS (MDX-100: ipilimumab®, Yervov®) and Pfizer
(CP675206: tremelimumab®). These have been evaluated in
patients with melanoma, renal cell carcinoma, and prostate can-
cer (amongst others), with response rates of 10–15% (reviewed in
Ménétrier-Caux et al., 2012). The observation that ipilimumab®
remarkably improved 1- and 2-year survival of patients with Stage
IV melanoma in clinical Phase II studies resulted in approval
for this indication by the US Food and Drug Administration.
However, the use of CTLA-4 blocking agents has been associated
with an increased risk of adverse effects including hypophysitis
(Blansfield et al., 2005), diarrhea (Wolchok et al., 2010), col-
itis (Berman et al., 2010), thyroiditis and arthritis (Bronstein
et al., 2011), and inflammatory skin rashes (Klein et al., 2009).
Recent observations demonstrate the capability of anti-CTLA-
4mAb to enhance the number of Treg cells without affecting
overall immune capacity (Maker et al., 2005; Ralph et al., 2010),
implies a direct activation of effector T cells by anti-CTLA-4mAb
(Ménétrier-Caux et al., 2012).
Other options include the use of Vascular Endothelial Growth
Factor Receptor (VEGFR) antagonists (sutent, sorafenib) (Ozao-
Choy et al., 2009; Adotevi et al., 2010). Sorafenib dramatically
reduces the number of peripheral and tumor-infiltrating Treg
cells in patients with metastatic renal cell carcinoma (Busse et al.,
2011; Desar et al., 2011) and sunitinibmonotherapy decreases the
number of peripheral Treg and has been shown to improve overall
survival in >70% of the patients (Adotevi et al., 2010). One can
hypothesize that combining CTLA-4 blockage with immunother-
apy might improve the overall effectiveness of these approaches.
Indeed, ONTAK-mediated elimination of Treg cells followed by
vaccination with RNA-transfected DCs significantly improves
the stimulation of tumor-specific T cell responses in patients
will renal cell carcinoma when compared with vaccination alone
(Dannull et al., 2005).
The use of agonistic mAbs against OX40 (CD134), a co-
stimulatory molecule of the TNF receptor family (Piconese
et al., 2008), represents a further approach to abrogate Treg cell-
mediated suppression of anti-tumor immunity (Kitamura et al.,
2009) and facilitate tumor rejection (Piconese et al., 2008).
Toll-like receptor (TLR2, TLR8, TLR9) agonists can also be
considered as promising tools for blocking Treg cell-mediated
immunosuppression. TLRs are involved in the recognition of
pathogen-associated molecular patterns (PAMPs) and the acti-
vation of processes that lead to innate immune recognition.
TLRs are expressed by a range of immune and non-immune
cells, including Treg cells, and they play an important role in
tumor immunotherapy (van Maren et al., 2008). Pre-treatment
of human Treg cells with a mixture of TLR2 ligands (Pam2CSK4,
Pam3CSK4, and FSL-1) abolishes Treg cell function by down-
regulating the Cdk inhibitor p27Kip1 and restoring Akt phospho-
rylation (Oberg et al., 2011). The synthetic bacterial lipoprotein
Pam3Cys-SK4, a TLR1/2 agonist which is capable of modulating T
cell immune responses, has been found to induce the expansion of
CD4+ CD25+ Treg cells and CD4+ CD25− effector T cells in the
absence of APCs (Liu et al., 2006a). Expanded Treg cells showed a
transient loss of suppressive activity. Furthermore, Pam3Cys-SK4
renders effector cells resistant to the suppression of Treg cells by
increasing IL-2 secretion. The group of Chu convincingly demon-
strated that Pam3Cys-SK4 treatment of mice with established
lung carcinoma, leukemia, and melanoma, respectively, induced
tumor regression and a long-lasting protective response against
tumor re-challenge (Zhang et al., 2011).
Pam3Cys-SK4 treatment also reduces the suppressive function
of Treg cells and enhances the cytotoxicity of tumor-specific cyto-
toxic T lymphocytes in vitro and in vivo (Zhang et al., 2011).
Treg cell function can be reversed by synthetic and natural ligands
for human TLR8 by a mechanism which is independent of DCs,
and the adoptive transfer of TLR8 ligand-stimulated Treg cells
into tumor-bearing mice enhances anti-tumor immunity (Peng
et al., 2005). Furthermore, a preoperative local administration of
the TLR9 agonist CpG B-type oligodeoxynucleotide (ODN) PF-
3512676 (formerly known as CPG 7909) lowers the frequency
of CD4+CD25high Treg cells in the sentinel lymph node of 23
patients with Stage I to III melanoma (Molenkamp et al., 2007).
Another promising immunotherapy involves blockage of
PD-1. Programmed death 1 (PD-1, CD279) is a key immune-
checkpoint receptor expressed by several T cell subsets including
Treg cells which plays an important role in the balance and
regulation of adaptive immune responses. Programmed death
ligand 1 (PD-L1) is constitutively expressed by B cells, DCs,
macrophages, and T cells and can also be found on different
tumor cells of human cancer (Jacobs et al., 2009). Activation-
induced upregulation of PD-L1 occurs via TLR4 and STAT1 sig-
naling (Loke and Allison, 2003; Freeman et al., 2006). Inhibition
of PD-1 and PD-L1 interactions enhances T cell responses in vitro
andmediates anti-tumor activity in pre-clinical models (Topalian
et al., 2012a). Upregulation of PD-1 and its ligandmight therefore
be associated with immune evasion and inhibition in tumor-
bearing hosts. Levels of T cells expressing PD-1 are upregulated
in patients with high-risk renal cell carcinoma and patients
with PD-1-positive T cells are at a significantly higher risk of
cancer-specific death compared with patients harboring low PD-
1-expressing T cells (Thompson et al., 2007). The blockage of
the PD-1/PD-L1 pathway using anti-PD-L1mAbs abrogates Treg
cell-mediated immune regulation in vitro and tolerance induc-
tion in vivo in mice (Kitazawa et al., 2007). Treg cell and PD-1
pathway signals have been studied in tumor-bearing patients.
The function and phenotype of Treg cells and the expression of
PD-1 and PD-L1 on different cell populations from the periph-
eral blood of patients with high-risk-resected stage III and IV
melanoma has been studied, and PD-1 blockage found to aug-
ment the generation of melanoma antigen-specific cytotoxic T
cells by stimulating their proliferation and, indirectly, by mask-
ing their suppression by Treg cells (Wang et al., 2009). PD-1
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blockage of Treg cells also diminished their inhibitory function
(Wang et al., 2009).
In a dose-escalation study, the anti-PD-1mAb BMS-936558
(also termedMDX-1106 andONO-4538) has been used as single-
agent in patients with advanced solid refractory tumors (Brahmer
et al., 2010). This Phase I study demonstrated a favorable safety
profile and preliminary evidence of clinical activity, thereby estab-
lishing the basis for a multiple-dose Phase I trial (Topalian
et al., 2012b). PD-1 blockage extended the spectrum of clinical
activity by immunotherapy beyond immunogenic tumor types,
such as melanoma and renal-cell cancer, to treatment-refractory,
metastatic non-small-cell lung cancer that is commonly not con-
sidered as being responsive to immunotherapy. This study and
a companion study with anti-PD-L1 antibody (Brahmer et al.,
2012) describe clinical activity with these agents validating the
impact of the PD-1/PD-L1 pathway for the treatment of certain
cancers. Phase II trials are under way (ClinicalTrials.gov num-
bers, NCT01354431 and NCT01358721), and Phase III studies
with anti-PD-1 antibody for the treatment of non-small-cell lung
cancer, melanoma, and renal cell cancer are being designed. Such
treatment regimens offer a promising therapeutic approach for
other tumor entities.
Given the difficulties that are associated with specifically tar-
geting regulatory T cells, interest in the use of cyclophosphamide
for inhibiting regulatory T cells and enhancing the induction
of anti-tumor immune responses has developed (Le and Jaffee,
2012). A current perspective on the potential use of cyclophos-
phamide for reducing/eliminating the negative impact of regu-
latory T cells on protective anti-tumor immunity and thereby
enhancing the efficacy of immunotherapeutic strategies has been
provided elsewhere (Le and Jaffee, 2012). The key elements of
the approach are that low-dose cyclophosphamide can enhance
tumor-specific immune responses, despite the fact that it tran-
siently decreases the frequency of regulatory T cell populations
(Machiels et al., 2001; Motoyoshi et al., 2006; Emens et al., 2009)
and that a metronomic (iterative, low-dose) approach results in a
more prolonged suppression of regulatory T cells which returns
to baseline within 4–6 weeks, even in the presence of continued
administration (Cerullo et al., 2011; Le and Jaffee, 2012). It is
also interesting to note that the downstream effects of cyclophos-
phamide treatment include the appearance of high avidity T effec-
tor cells (Ercolini et al., 2005; Laheru et al., 2008; Le and Jaffee,
2012).
It is important to appreciate that the influence of regula-
tory T cell populations on the induction of protective immunity
might extend beyond their effects on adaptive T cell immunity,
as CD4+CD25high Treg cells also inhibit the cytotoxic activity
of freshly isolated natural killer (NK) cells via their production
of TGF-β (Ghiringhelli et al., 2005a). CD4+CD25high Treg cells
from cancer patients effectively inhibit NK cell-mediated cyto-
toxicity (Wolf et al., 2003) and the depletion of CD4+CD25+
Treg cells enhances NKT cell-mediated anti-tumor immunity in
a murine mammary breast cancer model (Hong et al., 2010). It
is also apparent that the relationship between Treg cells and NK
cells is reciprocal, as NK-dependent increases in CCL22 secre-
tion selectively recruits Treg cells to the tumor microenvironment
(Mailloux and Young, 2009).
Given the apparent ability of the tumor microenvironment to
foster immune tolerance by generating and inducing the func-
tional capacity of regulatory T cell populations (Zou, 2005;
Whiteside, 2012), it is essential that we better understand
the influence that the tumor microenvironment and treatment
modalities have on the induction and progression of the pro-
tective anti-tumor immunity which is mediated by T cells and
NK cells.
MHC CLASS I EXPRESSION, NK CELLS, AND TUMOR
IMMUNITY
Approximately 40–90% of human tumors derived from various
MHC class I positive tissues are reported to be MHC class I
deficient, andMHC class I downregulation is an important mech-
anism of tumor escape from T cell-mediated immune responses
(Garrido et al., 1993; Restifo, 1996; Algarra et al., 1997; Zheng
et al., 1999; Johnsen et al., 2001; Groth et al., 2011). Decreased or
absent MHC class I expression is frequently associated with the
invasive and metastatic tumor phenotype (Garrido and Algarra,
2001; Bubenik, 2003).
Although the modulation of MHC class I expression has a
significant potential impact on the application of T cell-based
immunotherapies (Marincola et al., 2000), it does render tumor
cells to be more susceptible to NK cells which target MHC class
I negative (missing self) cells (Kärre et al., 1986; Ljunggren and
Kärre, 1990). Proof for the receptor inhibition model of the
“missing self” hypothesis comes from the work of Karlhofer
and Moretta who identified MHC I-specific inhibitory receptors
on the surface of NK cells such as human p58 (later termed
KIR2DL; Moretta et al., 1993), mouse-specific inhibitory Ly-49
receptors (Karlhofer et al., 1992) and the multi-species het-
erodimeric receptor complex CD94/NKG2D (Aramburu et al.,
1990; Carretero et al., 1997).
NK cells provide an essential defence against this response and
their importance is illustrated by the observation that downreg-
ulation of HLA class I is associated with an improved survival
of patients with non-small cell lung carcinoma (Ramnath et al.,
2006), uveal melanoma (Jager et al., 2002), breast carcinoma,
(Madjd et al., 2005) and colon cancer (Menon et al., 2002).
NK cells are large granular innate immune cells which account
for 5–20% of human lymphocytes and can spontaneously rec-
ognize virally-infected and cancer cells (Kiessling et al., 1975;
Langers et al., 2012). NK cells are characterized by the absence
of the characteristic T cell antigens CD3 and CD4 (Stobo
et al., 1973). Based on their expression of CD56 (Neuronal
Cell Adhesion Molecule) and CD16 (Fcγ receptor III; involved
in antibody-dependent cellular cytotoxicity, ADCC) peripheral
blood NK cells are grouped into two populations by the litera-
ture. The predominant population (90%) of NK cells comprises
CD56lowCD16high cells which express perforin and granzymes,
and exert cytotoxic functions including ADCC. CD56highCD16−
NK cells are mainly found in lymph nodes and comprise
only 5% of the NK cells in peripheral blood. Stimulated by
macrophage and DC-derived type I interferons (IFNs), IL-2 or
IL-15, CD56highCD16− NK cells are the primary producers of
IFN-γ and promote the activation of immune effector cells. An
additional population of CD56highCD16+ cells which accounts
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for 5% of peripheral blood NK cells exhibit unknown functions
(Nagler et al., 1989; Beziat et al., 2011). However, they have
been suggested to be an intermediate in the maturation from
CD56highCD16− to CD56lowCD16+ (Beziat et al., 2011).
NK cells express a large profile of inhibitory and activat-
ing receptors, the latter also comprising receptors for cytokines,
chemokines, and adhesion molecules (Table 2), andNK cell func-
tional activity depends on the balance of the signals that are deliv-
ered (Vivier et al., 2011). The intracellular domains of activating
receptors consist of immunoreceptor tyrosine-based activation
motives (ITAMs) or DAP10 with its transmembranic aspartic acid
residues, and these receptors include NKG2D and CD16 (Vivier
et al., 2004).
NKG2D belongs to the C-type lectin like family and recognizes
stress-inducible ligands such as MICA/B or ULBPs (Martinovic´
et al., 2011) and CD16 is the main inducer of ADCC. Receptors
that are characteristic of NK cells include natural cytotoxic-
ity receptors (NCRs) such as NKp46 which exert activating
functions. Inhibitory receptors are monomeric, associated with
immunoreceptor tyrosine-based inhibiting motifs (ITIMs) and
exert their function via the recognition of MHC class I and related
molecules (Vivier et al., 2004). One inhibitory receptor which rec-
ognizes HLA-E either alone or in complex with CD94 is NKG2A
(Langers et al., 2012).
Receptors of the killer-immunoglobulin (Ig) like receptor fam-
ily (KIRs) possess two or three extracellular Ig-like domains and
integrate incoming activating or inhibitory signals, but recognize
Table 2 | NK cell receptors.
Activating Inhibitory Chemotatic Cytokine Adhesion
receptors receptors receptors receptors receptors
mAct.Ly49 CEACAM-1 CCR2 IL-1R CD2
2B4 CD94/NKG2A CCR5 IL-2R DNAM-1
CD16 mInh.Ly49 CCR7 IL-12R β1 integrins
CD84 hKIR-L CXCR1 IL-15R β2 integrins
CD94/NKG2C KLRG-1 CXCR3 IL-18R
CRACC LAIR-1 CXCR4 IL-21R
hKIR-S hLILRB1 CXCR6 IFNAR
Ly9 mNKR-P1B CX3CR1
NKG2D mNKR-P1D hChem23R
mNKG2D-S TIGIT S1P5
NKp46
hNKp30
hNKp44
hNKp80
mNKR-P1C
NTBA
NK cells use a wide array of activating and inhibitory receptors which recognize
specific ligands expressed by target cells. MHC class I molecules expressed
on self cells are engaged by NK cell inhibitory receptors such as Ly49 in mice
(mInh.Ly49) and killer immunoglobulin-like receptors (KIR) in humans (h). In
contrast, expression of stress or pathogen-induced ligands, downregulation of
MHC class I on target cells as well as transformation-mediated ligand expression
are recognized by NK cell activating receptors (Table adapted from Vivier et al.,
2011, Science 331, 44–49).
MHC class I molecules with higher affinity than ligands of
activating KIRs (Martinovic´ et al., 2011). Autoimmunity is pre-
vented by the low expression of stress-induced ligands and the
high expression of MHC class I molecules (Vivier et al., 2008;
Langers et al., 2012).
NK CELLS AND THE TUMORMICROENVIRONMENT
One way via which tumors might avoid oncolysis is by altering
NK cell surface receptors. The expression of inhibitory recep-
tors NKG2A and CD85 on NK cells is upregulated in patients
with breast cancer and melanoma (Mamessier et al., 2011a,b).
Furthermore, the expression of activating receptors including
NKG2D, DNAM-1, Nkp30, and CD16 is downregulated in
patients with invasive breast cancer and metastasis to distant
sites, with the poorest prognosis being linked to the downregula-
tion of almost all activating receptors (Mamessier et al., 2011a,b;
Martinovic´ et al., 2011).
NKG2D expression is reduced in patients with gastric cancer
and this is likely to have clinical relevance given that NK cells
in patients with lymph node metastases exhibit lower NKG2D
expression than those patients with no metastases (Saito et al.,
2012). The same study demonstrated a lower expression of
NKG2D on NK cells within the primary tumor than their circu-
lating counterparts, and also that NKG2D expression increased
after surgery (Saito et al., 2012). Expression of the activation
receptors NKp30, NKp46, and NKG2D, but not NKp80 and 2B4
have been reported to be reduced in patients with cervical cancer
and with precursor lesions when compared to healthy controls
(Garcia-Iglesias et al., 2009). In vitro studies have demonstrated
that factors released by cervical cancer cell lines significantly
reduce NKG2D expression onNK cells and their cytotoxic activity
(Jimenez-Perez et al., 2012) and that ovarian and cervical cancer
cell lines expressing CD155 can downregulate the expression of
the DNAX accessary molecule 1 DNAM-1 on NK cells (Carlsten
et al., 2009).
It has recently been shown that the expression of tumor
necrosis factor superfamily ligands (TNFSFLs) by NK cells and
apoptotic tumor activity are suppressed in patients with head and
neck cancer. This suppression is tumor-dependent and possibly
mediated by soluble TNF superfamily receptors (solTNFSFRs)
(Baskic et al., 2012).
NK cell activity can also be modified by increasing the expres-
sion of inhibitory receptor ligands. Ovarian and cervical cancers
have been reported to exhibit an upregulated expression of HLA-
E, a ligand for the inhibitory CD94/NKG2A complex and the
upregulation of HLA-E and the infiltration of cytolytic T cell
populations could be neutralized by strong overexpression of the
NKG2A ligand (Gooden et al., 2011). Expression of the inhibitory
receptor CD158b and the proportion of NK cells expressing it
are increased in patients with non-small cellular lung cancer
(Al Omar et al., 2011).
With regards to NK cell function, the tumor microenviron-
ment and/or factors derived therefrom have been found to impair
NK cell-mediated anti-tumor protection. NK cell numbers can
be reduced, as has been found in patients with non-small cel-
lular lung cancer (NSCLC) and melanoma (Al Omar et al.,
2011; Martinovic´ et al., 2011), and this might impact on the
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overall potential of patients to elicit NK cell mediated immunity.
Degranulation and NK cell-mediated killing, as well as IFN-γ and
TNF-α secretion and induction of ADCC is impaired in patients
with metastatic breast cancer via a mechanism which appears to
involve TGFβ-1 and prostaglandin E2 (PGE2) (Holt et al., 2011;
Mamessier et al., 2011a,b). These findings have been confirmed by
studies that have related an NK cell functional profile with clini-
cal stages in melanoma and demonstrated that CD107a (a marker
for degranulation), IFN-γ and TNF-α levels as well as NKG2D
were downregulated, whereas CD158b, an inhibitory receptor was
upregulated (Martinovic´ et al., 2011). An interesting finding has
been that NK activity in the peripheral blood of patients with
breast cancer is lower than that in controls and also that the activ-
ity of NK cells in patients with HER2- cancers is significantly
lower than that in patients with HER2+ tumors (Dewan et al.,
2009). NK cell activity has also been shown to be reduced in
patients with cervical cancer (Garcia-Iglesias et al., 2009).
Tumors and macrophages produce H2O2 which can be
detected by flow cytometry using intracellular formation of
2′,7′-dichlorodihydrofluorescein as a measure of reactive oxygen
species. There is a negative correlation between CD56dim cell
numbers and H2O2 concentration in gastric and oesophageal
cancer (Izawa et al., 2011). This population is more susceptible to
apoptosis than CD56bright, and an observed impairment of ADCC
could be reversed by catalase (Izawa et al., 2011). PGE2 secretion
depends on the rate limiting enzyme cyclooxygenase-2 (COX-2)
which is overexpressed in some cancers. PGE2 also has a negative
influence on NK cell function via the receptors CD16, NCRs, and
NKG2D (Holt et al., 2011).
However, it remains unclear whether the impaired function-
ality of patient-derived NK cells is permissive of the development
of cancer or whether the observed altered phenotype and function
result from its presence.
EFFECT OF RADIOTHERAPY ON A TUMOR’S CAPACITY
TO INFLUENCE PROTECTIVE INNATE AND ADAPTIVE
IMMUNITY
The direct effect of irradiation on immune cells and its influence
of protective anti-tumor immunity has been considered elsewhere
in this Research Topic (Manda et al., 2012; Multhoff and Radons,
2012; Rödel et al., 2012; Rubner et al., 2012; Schmid andMulthoff,
2012). However, there is much less information relating to the
influence of radiotherapy on the tumor’s capacity to modify anti-
tumor immunity, particularly with regards to direct effects of
tumor-derived factors on infiltrating NK and immunoregulatory
T cell populations. In contrast to the immunosuppressive effects
of whole body irradiation, focal radiation such as that used for
treatment of many types of solid tumors has the capacity to influ-
ence the tumor microenvironment in a way which can enhance
the infiltration and the activation of immune cell types which
might foster and/or suppress tumor development (de Visser et al.,
2006; Shiao and Coussens, 2010).
Radiotherapy induces the expression of nuclear factor (NF)-κB
and this has a number of downstream effects with regards to
the expression of molecules that promote a pro-inflammatory
environment. Radiotherapy stimulates the migration and func-
tion of leukocytes via the release of cytokines such as TNF-α
(Shakhov et al., 1990), IL-1 (Mori and Prager, 1996), chemokines
(Wickremasinghe et al., 2004), the expression of adhesion
molecules such as ICAM-1 and E-selectin on vascular endothelial
cells within the tumor microenvironment (Iademarco et al., 1992;
Caldenhoven et al., 1994; Schindler and Baichwal, 1994; Hallahan
et al., 1996; Handschel et al., 1999). In vivo experiments using a
murine model of mammary carcinoma have demonstrated that
radiotherapy-induced expression of the chemokine CXCL16 is an
important mechanism which mediates the infiltration of CD8+ T
effector cells following treatment, as the recruitment of CD8+ T
cells and responsiveness to treatment are reduced in mice that are
deficient for its ligand (CXCR6) (Matsumura et al., 2008).
In vitro experiments using a range of different tumor cell types
also suggest that the induction of CXCL16 is a common response
to radiotherapy (Matsumura and Demaria, 2010). This could
have far-reaching effects with regards to the efficacy of radio-
therapy and the immunological mechanisms that are involved.
Stromal cell-derived factor (SDF)-1α also appears to an impor-
tant factor for to the immunological consequences of radiother-
apy, as inhibiting its pathway prevents macrophage infiltration
and delays tumor regrowth (Kozin et al., 2010).
Ionizing radiation also impacts signaling via pattern recog-
nition receptors (PRRs). These receptors interact with exoge-
nous PAMPs such as endotoxin and endogenous “alarmins” such
as high-mobility-group-box 1 (HMGB1), hyaluronan, and heat
shock (stress) proteins which together comprise the group of
danger-associated molecular patterns (DAMPs) (Bianchi, 2007;
Kawai and Akira, 2011). The export of DAMPs is achieved
by several mechanisms such as (1) leakage from necrotic cells,
(2) increased synthesis and post-translational modification in
response to inflammation, and (3) degradation of inactive pre-
cursors into TLR-mimetic cleavage products in inflammatory
environments (Mencin et al., 2009).
The impact of PRR signaling on radiation responses has been
documented by Shan and colleagues who demonstrated that
radiation-induced release of IL-12 and IL-18 frommacrophages is
accompanied by NF-κB activation and an upregulation of CD14
and TLR4/MD2 expression, thereby implying the involvement of
the Toll signaling pathway (Shan et al., 2007). On B cells and DCs,
TLR-related radioprotective 105 kDa (RP105) was identified as
being similar to TLR4 because of its ability to interact with the
MD2-like adaptor MD1 (Miyake et al., 1995; Fugier-Vivier et al.,
1997). RP105/MD1 directly interacts with TLR4/MD2, thus abol-
ishing the LPS binding capacity of the complex (Divanovic et al.,
2005). Together with its ability to regulate TLR4 signaling in vitro
and LPS responses in vivo, RP105 can be considered as being a
negative regulator of TLR4 responses.
From these observations it can be assumed that pro-
inflammatory responses to radiation and TLR signaling not only
increase the impact of tumor-promoting factors in the tumor and
the microenvironment, but also might function as crucial targets
in radiotherapy. It is interesting to note that the radiation-induced
release of HMGB1 by dying tumor cells enables the manifesta-
tion of tumor antigen-specific T cell immunity (Apetoh et al.,
2007). This pathway depends on the interaction of HMGB1 with
TLR4 expressed on DCs. During chemotherapy or radiotherapy,
DCs require signaling through TLR4 for efficient processing and
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cross-presentation of antigen from dying tumor cells. Moreover,
patients with breast cancer who carry a TLR4 “loss-of-function”
allele relapse more quickly after radiotherapy and chemotherapy
than those carrying the normal TLR4 allele.
These results delineate a clinically-relevant immunoadjuvant
pathway which is triggered by tumor cell death. Silencing of
HMGB1 expression by anHMGB1-specific RNAi lentiviral vector
has been shown to reduce matrix metalloproteinase 9 (MMP9)
expression and metastatic capacity in MGC-803 gastric carci-
noma cells (Song et al., 2011). HMGB1-specific silencing also
significantly decreased cell proliferation and sensitized cells to
oxaliplatin-induced apoptosis mediated via the caspase-3 path-
way (Song et al., 2011), rendering HMGB1 a promising target
structure in cancer therapy.
An intriguing novel observation has reported by Kono
and colleagues who demonstrated that 38% of patients with
oesophageal squamous cell carcinoma harbored elevated HMGB1
serum levels after chemoradiotherapy and showed concomi-
tant tumor antigen-specific T cell responses (Suzuki et al.,
2012). The same study revealed an upregulated HMGB1
expression within the tumor microenvironment in patients
with ESCC after preoperative chemoradiotherapy, but not in
those without chemoradiotherapy, and the degree of HMGB1
positively correlated with patient survival (Suzuki et al.,
2012). Both, irradiation and chemotherapy induces upreg-
ulation of HMGB1 and the chaperone protein calreticulin.
Furthermore, HMGB1 is able to induce maturation of DCs,
implying that chemoradiation induces tumor antigen-specific
T cell responses, and that chemoradiation-mediated HMGB1
production is related to clinical outcome (Suzuki et al.,
2012).
Using an in vitro approach, in which the transmigration of T
cell populations toward supernatants derived from primary cul-
tures of tumor cells derived from patients with head and neck
carcinomas, Schmidtner et al. (2009) have demonstrated that
supernatants from irradiated cells significantly decrease the trans-
migration of CD4+CD25highFoxp3+ Treg cells, yet had no effect
on the transmigration of CD4+CD25− T cells. The observed
effects on cell migratory properties have been attributed to
treatment-associated increases chemokine (C-C motif) ligand 22
(CCL22) levels in the tumor cell supernatants (Schmidtner et al.,
2009). These findings contrast with the effects that are seen fol-
lowing hyperthermia treatment which appears to promote the
migration of CD4+CD25highFoxp3+ Treg cells (Schmidtner et al.,
2009). These potentially important findings indicate that radio-
therapy may play some role in reducing the capacity of tumors
to promote the prevalence of CD4+CD25highFoxp3+ Treg cells
in the tumor microenvironment and might, as a consequence,
facilitate the induction or protective innate and adaptive tumor
immunity.
In an attempt to increase the therapeutic benefit of irradiation,
several studies have combined molecular oncology therapeutics
with radiation. Radiation sensitization, in which cytotoxic
enhancers co-operate with radiation within the radiation field,
aims to produce a greater (synergistic) anti-tumor effect than
would be expected from simple additive cell killing (Zaidi
et al., 2009). Oncolytic viruses represent prime candidates for
enhancing the immunogenicity of the tumor microenvironment.
Oncolytic virotherapy may be immunomodulatory via tumor cell
death, production of endogenous danger signals, the release of
tumor-derived cytokines and direct effects upon cells of the innate
immune system (Prestwich et al., 2008).
Pre-clinical models suggest that tumor viral therapy medi-
ates an early influx of immune cells, such as macrophages and
NK cells (Benencia et al., 2005; Diaz et al., 2007). These changes
within the tumor hold the potential to alter the pre-existing
immunosuppressive microenvironment, in favor of the genera-
tion of therapeutic immune responses. DCs are critical for the
subsequent generation of antigen-specific or adaptive immune
responses. According to Prestwich et al. (2008), the outcome
of the innate response is finely balanced between promotion
of tumor clearance and viral clearance that limits the efficacy.
Strategies that involve combining oncolytic virotherapy with
external beam radiotherapymay help to exploit synergies between
the two treatment modalities (Hingorani et al., 2007; Harrington
et al., 2008).
Melcher and colleagues have demonstrated a synergy between
oncolytic reovirus RT3D, a naturally occurring nonpathogenic,
double-stranded RNA virus isolated from the respiratory and gas-
trointestinal tracts of humans and external beam radiotherapy
in tumor cell lines in vitro and in three different in vivo tumor
models (Twigger et al., 2008). The same group has now com-
pleted a Phase I dose-escalation study of this combination strategy
in patients receiving two different dose schedules of palliative
radiotherapy and confirmed the safety and tolerability of this
approach (Harrington et al., 2010). The study further showed that
virus is not shed after administration, thereby opening the way
for outpatient treatment regimens. Most importantly, the ease
of virus administration and the fact that there was no exacerba-
tion of radiation-induced toxicity strongly support development
of this combinatory treatment in patients with newly diagnosed,
radiocurable cancers.
Several potentially positive theoretical interactions exist
between RT3D and radiotherapy. Tumor radiation resistance is,
at least partly, mediated by the Ras signaling pathway (McKenna
et al., 2003). Moreover, activating Ras mutations, EGFR overex-
pression, and phosphorylation of Akt and phosphoinositide-3-
kinase have been found as being associated with radioresistance
in vitro and, with respect to EGFR and Akt, to the failure of radio-
therapy in cancer patients (Gupta et al., 2002, 2003; McKenna
et al., 2003). Blockage of the Ras signaling pathway sensitizes cells
to radiation-induced cytotoxicity (Bernhard et al., 1996; Russell
et al., 1999).
Radiotherapy in combination with oncolytic reovirus also
represents a promising immunotherapeutic approach, as radio-
therapy enhances T cell trafficking (Lugade et al., 2005), antigen
presentation, and T cell recognition of tumor cells (Reits et al.,
2006). Radiotherapy is also locally immunosuppressive by killing
lymphocytes, and the optimal combination to enhance anti-
tumor immune responses will require careful consideration of
dose fractionation and treatment scheduling.
Another potentially important element of the tumor microen-
vironment which might be altered following the induction of
cell death following radiotherapy relates to the release of heat
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shock proteins. Although typically regarded as being intracellu-
lar proteins, stress proteins, including members of the 60 and
70 kDa families (Hsp60, Hsp70) can be released from a variety
of cell types and have been identified in the peripheral circula-
tion in a number of healthy and diseased states (Pockley et al.,
1998, 1999, 2000; Rea et al., 2001; Pockley, 2003; Henderson
and Pockley, 2010; Henderson et al., 2010). In addition to act-
ing as potent inducers of inflammatory immunity, these proteins
can also ameliorate inflammatory events/conditions by induc-
ing/activating regulatory T cell populations (Borges et al., 2012)
or by reducing T cell responses and the stimulatory capacity of
monocyte-derived DCs (Stocki et al., 2012).
Hsp70 can be released from human glioma, prostate can-
cer cell lines, the human erythroleukemic cell line K562, and
the 4T1 breast carcinoma cell line (Guzhova et al., 2001; Wang
et al., 2004; Bausero et al., 2005; Evdonin et al., 2006; Mambula
and Calderwood, 2006a,b). Although the relationship between
intracellular Hsp70 expression and release has yet to be clari-
fied, increasing the expression of Hsp70 by transfecting prostate
cancer cells with cDNA encoding for human Hsp70 enhances
their release of Hsp70 (Wang et al., 2004), as does heat treatment
(Mambula and Calderwood, 2006a). Non-lethal heat, IFN-γ,
and IL-10 also increase Hsp70 release from K562 and 4T1 cells
(Bausero et al., 2005). Although in a small cohort of patients, it
has been reported that radiotherapy increases circulating Hsp70
levels in patients with prostate cancer and it might be that this
reflects increases in Hsp70 levels within the tumor microenviron-
ment (Hurwitz et al., 2010).
Although one study reports that Hsp70 release from prostate
cancer cells protects against tumor growth (Wang et al., 2004),
presumably via its capacity to induce tumor-specific immunity
(Calderwood et al., 2005, 2006), Hsp70might also adversely influ-
ence anti-tumor immunity by activating CD4+CD25high Treg
cells via its capacity to interact with TLRs expressed thereon.
Released Hsp70 might also have direct effects on tumor cell
survival following radiotherapy, as radiation-induced tumor cell
killing has been shown to be significantly enhanced by the addi-
tion of Hsp70 protein via a mechanism which appears to involve
necrosis rather than apoptosis (Schilling et al., 2009).
In addition to the secretion of Hsp70 from viable tumor cells
and its inevitable release from necrotic cells within the tumor
mass, a form of Hsp70 is frequently expressed on the membranes
of a number of cancers, and metastases derived therefrom, but
not on their non-malignant counterparts (Multhoff et al., 1995,
1997; Botzler et al., 1996, 1998; Multhoff and Hightower, 1996;
Multhoff et al., 2001; Gehrmann et al., 2002; Shin et al., 2003;
Multhoff, 2007, 2009). It is also the case that the expression of
this membrane form of Hsp70 is enhanced by clinically applied
interventions such as radio- and chemotherapy (Gehrmann et al.,
2008a,b, 2010) (Figure 1).
FIGURE 1 | Potential immunological benefits of tumor irradiation. Increased recruitment of immunoregulatory T cell populations could negatively impact
on protective anti-tumor immunity.
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Membrane Hsp70 acts as a tumor-specific recognition struc-
ture for CD94+ NK cells and, in the presence of Hsp70 and
cytokine (IL-2/IL-15) co-activation, it enhances the capacity of
NK cells these cells to kill membrane Hsp70 positive tumor cells
(Botzler et al., 1996, 1998; Gross et al., 2003a,b). Membrane
Hsp70 expressing tumors can also be imaged and targeted using
a specific monoclonal antibody (cmHsp70.1) or a glycosylated
recombinant human granzyme B (Stangl et al., 2010, 2011;
Gehrmann et al., 2011, 2012). It might therefore be that the
release of heat shock proteins such as Hsp70 into the tumor
microenvironment by radiation-induced cell death has a num-
ber of immunoregulatory effects that influence many aspects of
protective anti-tumor immunity (Figure 1).
CONCLUDING STATEMENT
Although it is known that tumors can have a range of
immunoregulatory effects that can have tumor-suppressive and
tumor-stimulatory properties, an improved insight into the
mechanisms and factors involved is required in order to design
strategies for promoting the efficacy of therapeutic interven-
tions such as radiotherapy. Focal radiotherapy can elicit anti-
tumor immunity by the following mechanisms: (1) boosting
trafficking of APCs to the tumor site, (2) augmenting antigen
uptake of irradiated tumor cells; (3) increasing the matu-
ration of APCs, (4) inducing maturation of immune effec-
tor cells in order to generate a robust immune response,
and (5) limiting the immunomodulatory capacity of Treg cell
populations.
Accumulation of Treg cells in cancer patients is a major factor
in tumor immune escape. Targeting of these cells might thus pro-
vide a mechanism by which anti-tumor immune responses could
be restored. Immunotherapeutic strategies which target Treg cells
and deplete functional Treg cells from the tumor microenviron-
ment cells appear to shift the immune balance in support of
effective anti-cancer immune responses. It is likely that effec-
tive anti-cancer strategies will depend on multimodal approaches
which combine immunotherapy with targeted therapies that
stimulate protective immune effector activity and downregulate
the suppressive effects of Treg cells.
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